Disc Medicine
Clinical-stage biopharma developing first-in-class therapies for hematologic disorders, from rare blood diseases to chronic conditions
Highlights
- New on EvolcAdded 2026-11-11
About Disc Medicine
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for hematologic disorders, including rare blood disorders and more widespread chronic conditions. Its named pipeline programs are bitopertin, DISC-0974 and DISC-3405, and the company also runs a PPIX Testing Program and publishes research under Disc Publications.
The company's work is directed at patients living with serious hematological diseases.
Disc Medicine is headquartered in Watertown, Massachusetts, United States. It is publicly listed and files with the SEC; its site lists quarterly results and analyst coverage. Its CEO is John Quisel. The company listed 19 open roles, mostly hybrid in Massachusetts, across commercial, medical affairs, clinical development, legal and finance, plus remote medical science liaison positions.
Product: Investigational first-in-class therapeutics for hematologic disorders, including bitopertin, DISC-0974 and DISC-3405.
Jobs at Disc Medicine
More biotech & pharma companies
Drug Hunter
Drug discovery intelligence and research tools for pharmaceutical scientists, drug discovery teams and investorsRemote-friendlyDyne Therapeutics
Targeted genetic therapies for people with genetically driven neuromuscular diseasesNew on EvolcDyno Therapeutics
AI-enabled genetic technology development for biotechnology and medicine developersNew on EvolcEarli
Develops genetic switches that activate in cancer cells for cancer detection and therapeutic applicationsNew on EvolcEmeraldcloudlab
Remotely controlled life science lab letting pharma, biotech and academic teams run wet-lab experiments through softwareNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Response headerserver
Frontend frameworks
- Next.jsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- ReactMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Related technologyimplied by Next.js
Hosting
- NetlifyHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-nf-request-id
- Response headerx-nf-request-id
- Response headerx-nf-request-id
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.